Drug maker Sanofi swoops for biotech company in $11.6bn deal
French drug maker Sanofi, which has operations in the North West and Yorkshire, is to acquire biotechnology company Bioverativ for $11.6bn.
Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have agreed a deal which will see Sanofi acquire all of the outstanding shares of Bioverativ for $105 per share in cash.
Sanofi, which employs hundreds of people in Holmes Chapel and in Sheffield, said the deal expands its presence in specialty care and strengthens it... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...